US Broker Ratings

Schrodinger, Inc. (SDGR) Stock Analysis: Unveiling a 47% Upside Potential Amidst Robust Revenue Growth

Schrodinger, Inc. (NASDAQ: SDGR) stands as a beacon of innovation in the healthcare sector, specifically within the health information services industry. With a market capitalization of $1.36 billion, this New..

QuidelOrtho Corporation (QDEL) Stock Analysis: Unpacking a 25% Potential Upside

For investors seeking opportunities in the healthcare sector, QuidelOrtho Corporation (NASDAQ: QDEL) presents an intriguing case with its diagnostic testing solutions that span multiple business units, including Labs, Transfusion Medicine,..

Amicus Therapeutics, Inc. (FOLD): Investor Outlook with 3.86% Potential Upside

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is making waves in the biotechnology sector with its strategic focus on rare diseases, a niche that offers both challenges and opportunities for growth. Headquartered..

Novavax, Inc. (NVAX) Stock Analysis: Exploring a 76% Potential Upside in the Biotechnology Sector

Novavax, Inc. (NVAX) is a name that has been on the radar for investors interested in the biotechnology sector, especially those focused on vaccine development. With a market capitalization of..

Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Closer Look at its 113% Upside Potential

Dyne Therapeutics, Inc. (NASDAQ: DYN), a clinical-stage biotechnology firm, is capturing investor attention with an impressive potential upside of 113.25%. Specializing in therapeutics for neuromuscular diseases, the company is at..

Beam Therapeutics Inc. (BEAM) Investor Outlook: Navigating Biotech with a 71% Upside Potential

Investors eyeing opportunities in the biotech sector may find Beam Therapeutics Inc. (BEAM) a compelling case, especially given its potential upside of 71.12%. This Massachusetts-based company, specializing in precision genetic..

CG Oncology, Inc. (CGON) Investor Outlook: Exploring the 76.61% Potential Upside in Cutting-Edge Bladder Cancer Therapies

CG Oncology, Inc. (NASDAQ: CGON) is making waves in the biotechnology sector with its innovative approach to bladder cancer treatment. Based in Irvine, California, this late-stage clinical biopharmaceutical company is..

Addus HomeCare Corporation (ADUS) Stock Analysis: Exploring a 29% Potential Upside in the Healthcare Sector

Investors seeking opportunities in the healthcare sector might find Addus HomeCare Corporation (NASDAQ: ADUS) a compelling consideration. This Frisco, Texas-based company, with a market cap of $2.03 billion, provides essential..

Artivion, Inc. (AORT) Growth Potential: Analyst Ratings Show 15.98% Upside for Medical Device Innovator

Artivion, Inc. (NASDAQ: AORT), a prominent player in the healthcare sector, specifically within the medical devices industry, has been capturing investor attention with its impressive growth trajectory and robust product..

Kestra Medical Technologies (KMTS) Stock Analysis: Strong Revenue Growth and 19% Potential Upside

Investors have been increasingly eyeing Kestra Medical Technologies, Ltd. (KMTS), a burgeoning player in the healthcare sector specializing in medical instruments and supplies. With its current market capitalization standing at..

UFP Technologies, Inc. (UFPT) Stock Analysis: Exploring a 38.85% Potential Upside in the Medical Device Sector

UFP Technologies, Inc. (NASDAQ: UFPT) is a noteworthy player in the healthcare sector, specifically within the medical devices industry. With its headquarters in Newburyport, Massachusetts, the company has carved out..

ARS Pharmaceuticals, Inc. (SPRY): Investor Outlook Reveals a Compelling 162% Upside Potential

ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a promising player in the biotechnology sector, has captured investor attention with a standout potential upside of 162.84%. As a biopharmaceutical company focused on innovative..

Acadia Healthcare (ACHC) Stock Analysis: Unveiling a 48.56% Potential Upside

Acadia Healthcare Company, Inc. (NASDAQ: ACHC), a prominent player in the U.S. healthcare sector, specifically in the medical care facilities industry, is catching the attention of investors with its significant..

Vericel Corporation (VCEL) Stock Analysis: Exploring a 48% Potential Upside in the Biotech Sector

Vericel Corporation (NASDAQ: VCEL), a prominent player in the biotechnology sector, stands out with a substantial potential upside of 48.33%. As a commercial-stage biopharmaceutical company, Vericel is making significant strides..

MannKind Corporation (MNKD) Stock Analysis: Unveiling a 71% Upside Potential with Strong Buy Ratings

MannKind Corporation (NASDAQ: MNKD), a prominent player in the biotechnology sector, has caught the attention of investors with a compelling growth narrative and significant upside potential. As a biopharmaceutical company..

GeneDx Holdings Corp. (WGS) Investor Outlook: Robust Growth Potential with a 29.95% Upside

GeneDx Holdings Corp. (NASDAQ: WGS), a prominent player in the healthcare sector, is generating significant buzz among investors due to its impressive growth trajectory and the potential for nearly 30%..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a 14.44% Potential Upside in the Biotech Sector

Protagonist Therapeutics, Inc. (PTGX), a promising player in the biotechnology sector, is capturing investor attention with its innovative pipeline and significant market potential. Headquartered in Newark, California, this biopharmaceutical company..

Liquidia Corporation (LQDA) Stock Analysis: Unveiling a 36.86% Potential Upside in the Biotechnology Sector

Liquidia Corporation (NASDAQ: LQDA) is making waves in the biotechnology sector, capturing the attention of investors with a staggering 36.86% potential upside. Based in Morrisville, North Carolina, Liquidia is a..

ICU Medical, Inc. (ICUI) Stock Analysis: Exploring a 25% Upside Potential with Strong Buy Ratings

ICU Medical, Inc. (NASDAQ: ICUI), a key player in the healthcare sector specializing in medical instruments and supplies, has caught the attention of investors with its robust market presence and..

Merus N.V. (MRUS) Stock Analysis: Exploring a 7.78% Potential Upside Amid Biotech Innovations

Merus N.V. (NASDAQ: MRUS), a Netherlands-based clinical-stage biotechnology company, has been capturing attention in the healthcare sector with its innovative approach to antibody therapeutics. Operating at the cutting edge of..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds